Efficacy of tulathromycin in the treatment and prevention of natural outbreaks of bovine respiratory disease in European cattle.
The efficacy of tulathromycin in the treatment (phase 1) and prevention (phase 2) of bovine respiratory disease (BRD) was evaluated on commercial farms in France, Germany, Italy, and Spain. In phase 1, commingled cattle with clinical BRD were treated with tulathromycin (n = 128) or florfenicol (n = 125) on day 0. Similar percentages of animals showed sustained clinical improvement at day 14 (tulathromycin 83.3% versus florfenicol 81.0%) and had not relapsed by day 60 (tulathromycin 63.3% versus florfenicol 58.4%). In phase 2, healthy in-contact cattle were treated with tulathromycin (n = 492), tilmicosin (n = 494), or saline (n = 265) on day 0. Significantly more (P = .0001) tulathromycin-treated cattle remained healthy to day 14 (92.4%) than tilmicosin-treated (83.7%) or saline-treated (63.7%) cattle, and this was maintained through day 60 (tulathromycin 85.4% versus tilmicosin 75.1% and saline 56.2%). Tulathromycin was highly effective in the treatment and prevention of BRD.
Godinho
Kevin S
KS
Veterinary Medicine Research and Development, Pfizer Ltd, Sandwich, Kent, UK.
Wolf
Regina M-L G
RM
Sherington
John
J
Rowan
Tim G
TG
Sunderland
Simon J
SJ
Evans
Nigel A
NA
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002417:Cattle; D004187:Disaccharides / Q000008:administration & dosage / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control / Q000662:veterinary*; D005060:Europe / Q000453:epidemiology; D044138:Haemophilus somnus / Q000302:isolation & purification; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use; D016978:Mannheimia haemolytica / Q000302:isolation & purification; D045682:Mycoplasma bovis / Q000302:isolation & purification; D016979:Pasteurella multocida / Q000302:isolation & purification; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control*; D013839:Thiamphenicol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015645:Tylosin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D018942:Macrolides; C035534:florfenicol; D013839:Thiamphenicol; C485204:tulathromycin; C052319:tilmicosin; D015645:Tylosin